The role of aerodynamic drag in propagation of interplanetary coronal mass ejections

Context. The propagation of interplanetary coronal mass ejections (ICMEs) and the forecast of their arrival on Earth is one of the central issues of space weather studies. Aims. We investigate to which degree various ICME parameters (mass, size, take-off speed) and the ambient solar-wind parameters (density and velocity) affect the ICME Sun-Earth transit time. Methods. We study solutions of a drag-based equation of motion by systematically varying the input parameters. The analysis is focused on ICME transit times and 1 AU velocities. Results. The model results reveal that wide ICMEs of low masses adjust to the solar-wind speed already close to the sun, so the transit time is determined primarily by the solar-wind speed. The shortest transit times and accordingly the highest 1 AU velocities are related to narrow and massive ICMEs (i.e. high-density eruptions) propagating in high-speed solar wind streams. We apply the model to the Sun-Earth event associated with the CME of 25 July 2004 and compare the results with the outcome of the numerical MHD modeling

A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low- and middle-income countries.

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a new virus that has never been identified in humans before. COVID-19 caused at the time of writing of this article, 2.5 million cases of infections in 193 countries with 165,000 deaths, including two-third in Europe. In this context, Oncology Departments of the affected countries had to adapt quickly their health system care and establish new organizations and priorities. Thus, numerous recommendations and therapeutic options have been reported to optimize therapy delivery to patients with chronic disease and cancer. Obviously, while these cancer care recommendations are immediately applicable in Europe, they may not be applicable in certain emerging and low- and middle-income countries (LMICs). In this review, we aimed to summarize these international guidelines in accordance with cancer types, making a synthesis for daily practice to protect patients, staff and tailor anti-cancer therapy delivery taking into account patients/tumour criteria and tools availability. Thus, we will discuss their applicability in the LMICs with different organizations, limited means and different constraints

The effects of aromatase inhibitors on lipids and thrombosis

Oestrogen is known to influence blood lipid levels and though its cardioprotective effects are less clear than once thought, there remains concern that reduction of oestrogen levels during hormonal treatment for breast cancer may have an adverse effect on cardiovascular risk. While tamoxifen has been shown to improve lipid profiles, the aromatase inhibitors have a very different mode of action and do not possess the oestrogen-agonistic effects of tamoxifen. At present, there are few data on the effects of these agents on lipid profiles. Available data are mixed, but suggest that the different aromatase inhibitors have different effects on lipid profiles. Some studies show anastrozole as generally having little effect on lipids, while others have indicated adverse effects on lipid profiles/increased hypercholesterolaemia. Letrozole has been associated with adverse effects on lipid profiles in some studies, including BIG 1-98, but short-term data from randomised trials do not show increased cardiovascular morbidity. By contrast, exemestane, which has been studied in slightly more detail, may either have little effect or may be associated with slightly improved lipid profiles. In general, the changes have been small and are likely to be of little relevance in women with advanced breast cancer, but if these agents come to be used in early breast cancer, their impact on lipid profiles may become more important. Many studies are currently underway with the aromatase inhibitors, with safety assessments including monitoring lipid levels. The results of these studies are keenly awaited

Exposure to depleted uranium does not alter the co-expression of HER-2/neu and p53 in breast cancer patients

<p>Abstract</p> <p>Background</p> <p>Amongst the extensive literature on immunohistochemical profile of breast cancer, very little is found on populations exposed to a potential risk factor such as depleted uranium. This study looked at the immunohistochemical expression of HER-2/neu (c-erbB2) and p53 in different histological types of breast cancer found in the middle Euphrates region of Iraq, where the population has been exposed to high levels of depleted uranium.</p> <p>Findings</p> <p>The present investigation was performed over a period starting from September 2008 to April 2009. Formalin-fixed, paraffin-embedded blocks from 70 patients with breast cancer (62 ductal and 8 lobular carcinoma) were included in this study. A group of 25 patients with fibroadenoma was included as a comparative group, and 20 samples of normal breast tissue sections were used as controls. Labeled streptavidin-biotin (LSAB+) complex method was employed for immunohistochemical detection of HER-2/neu and p53.</p> <p>The detection rate of HER-2/neu and p53 immunohistochemical expression were 47.14% and 35.71% respectively in malignant tumors; expression was negative in the comparative and control groups (p < 0.05).</p> <p>HER-2/neu immunostaining was significantly associated with histological type, tumor size, nodal involvement, and recurrence of breast carcinoma (<it>p </it>< 0.05), p53 immunostaining was significantly associated with tumor size, nodal involvement and recurrence of breast cancer (<it>p </it>< 0.05). There was greater immunoexpression of HER-2/neu in breast cancer in this population, compared with findings in other populations.</p> <p>Both biomarkers were positively correlated with each other. Furthermore, all the cases that co-expressed both HER-2/neu and p53 showed the most unfavorable biopathological profile.</p> <p>Conclusion</p> <p>P53 and HER-2/neu over-expression play an important role in pathogenesis of breast carcinoma. The findings indicate that in regions exposed to high levels of depleted uranium, although p53 and HER-2/neu overexpression are both high, correlation of their expression with age, grade, tumor size, recurrence and lymph node involvement is similar to studies that have been conducted on populations not exposed to depleted uranium. HER-2/neu expression in breast cancer was higher in this population, compared with results on non-exposed populations.</p

Dynamics of coronal mass ejections

Context. Coronal and interplanetary propagation of coronal mass ejections (CMEs) is strongly affected by aerodynamic drag. Aims. The dependence of the drag acceleration on the mass of the CMEs is investigated to establish a quantitative empirical relationship, which might be important in semi-empirical space-weather forecasting. Methods. We employ a large sample of CMEs observed in the radial distance range of 2–30 solar radii by the Large Angle and Spectrometric Coronagraph on board the SoHO mission to statistically analyze the acceleration-velocity relationship in subsamples of various classes of CME masses. Results. It is demonstrated that the slope and the v-axis intercept of the anti-correlation of the CME acceleration a and velocity v depend on the mean mass of CMEs included in the sample. The slope k of the correlation is less steep for subsamples of higher masses, revealing that massive CMEs are less affected by the aerodynamic drag. Furthermore, it is found that the v-axis intercept is shifted to higher velocities for subsamples of higher masses. This indicates that, on average, the driving force is greater in more massive CMEs. Conclusions. The empirically established dependence of the $a(v)$ slope on the CME mass is very close to the dependence $k\propto m^{-1/3}$ which follows from the physical characteristics of the aerodynamic drag